Recent head-to-head clinical data reveals that Ingrezza demonstrates a significantly higher VMAT2 target occupancy compared to Austedo XR, making it a more effective option in treating conditions such as tardive dyskinesia. This finding is crucial as VMAT2 inhibitors play a vital role in managing neurotransmitter regulation associated with movement disorders. Both drugs are essential in treating tardive dyskinesia and other similar conditions, but this new evidence positions Ingrezza as potentially more advantageous due to its enhanced binding efficiency. The study provides valuable insights, suggesting that Ingrezza could offer improved outcomes for patients seeking effective treatments. As the medical community continues to explore optimal therapies for movement disorders, this data adds an important layer to the decision-making process. Patients and healthcare providers might gravitate towards Ingrezza, considering these promising results. This information not only benefits the patient communities but also guides the healthcare professionals in selecting more suitable therapies tailored to individual needs.
Psychiatric TimesNew data shows the significant income gap South Australian buyers face to own a home
October 11, 2026
New data reveals the growing income gap that South Australian (SA) homebuyers must overcome to enter the housing market. As property prices rise steadily, many